With this in mind, we sought to identify additional CAR T cell targets in DIPG combining cell surface proteomics,14 with RNAseq and validated human epidermal growth factor receptor 2 (HER2), an oncogene, as an appropriate target for DMG/DIPG recently shown to be expressed in patients with DIPG.15 Amplification and overexpression of HER2 has been reported in many cancers including breast and ovarian cancers and have been well explored in glioma16,17 leading to it being considered a pan-cancer target for many indications. This evidence concerns the gene ERBB2 and ovarian cancer.